The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first medication for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. This marks a significant advancement in OSA management.

In clinical trials, Zepbound demonstrated a substantial reduction in apnea-hypopnea index (AHI) scores, indicating fewer breathing interruptions during sleep. 

Participants also experienced significant weight loss, which is believed to contribute to the improvement in OSA symptoms.Following the approval, stocks of sleep apnea device manufacturers, such as ResMed and Inspire Medical Systems, saw declines. This suggests that Zepbound may offer an alternative to traditional positive airway pressure (PAP) therapies, which some patients find uncomfortable.

Beyond improving sleep apnea, Zepbound has shown potential in reducing the progression of heart failure and kidney disease, highlighting its multifaceted health benefits.